CV Sciences (CVSI) Acquisitions (2013 - 2024)
CV Sciences (CVSI) posted Acquisitions of $4000.0 for Q4 2024, up 111.76% sequentially from -$34000.0 in Q3 2024, and down 97.44% YoY from $156000.0 in Q1 2024.
CV Sciences (CVSI) Acquisitions (2013 - 2024) Analysis & Trends
CV Sciences has reported Acquisitions for 3 years, with the latest figure at $4000.0 in Q4 2024.
- Quarterly Acquisitions fell 97.44% year-over-year to $4000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2025 was -$30000.0 (down 123.81% YoY) and the FY2024 annual result came in at $10000.0, down 93.59% from the prior year.
- Acquisitions climbed to $4000.0 in Q4 2024 per CVSI's latest filing, from -$34000.0 in the prior quarter.
- Over five years, Acquisitions peaked at $156000.0 in Q4 2023 and troughed at -$34000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | CV Sciences | 4.10 Mn | 3.84 Mn | 1.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 4,000.00 |
| Sep 30, 2024 | -34,000.00 |
| Dec 31, 2023 | 156,000.00 |
| Mar 31, 2013 | 50,775.00 |